The cure rate of new crown is 95%? Doubts about Israel’s new crown medicine

Doubt 2: does new coronavirus have “specific drug”? Since the outbreak of the epidemic, Israel has made a lot of innovative discoveries in the field of new crown drugs, but few of them can finally see the results

.

(this article is first published in titanium media app by Yang Yaru) —- gorgeous segmentation line ——– happy new year from titanium media! At the beginning of the new year, Ms

.

This phenomenon is exactly the “cytokine storm” mentioned above, which is usually the cause of death of patients

.

Professor nadir Arber of Israel’s Tel Aviv sulaski Medical Center said that at present, other related drugs in the world either choose to inhibit a specific cytokine or widely inhibit it, leading to serious side effects, while exo-cd24 is a “cytokine storm” center directly targeted at the lung, which has a wide range of effects in a specific range without side effects effect

.

The specific situation of 30 patients is not clear, so it is difficult to represent the new crown patients, and there are many restrictions on the 100% effective rate, which is not mentioned in the press release

.

Among the “special drugs” in the new crown, the new entrant exo-cd24 has not yet been verified, while the long-time famous redcivir is high and low

.

In June, novel coronavirus pneumonia could reduce the in-hospital mortality of 1/3 in severe acute respiratory syndrome patients, but the guidelines in China are cautious about the use of drugs, University of Oxford reported in nature news last year

.

Click to follow Zhao hejuan’s video number [receiving method] ↓

.

According to the previous introduction of “medical video screen”, there are three mainstream schemes for drug R & D and trial of new coronavirus

.

It is too early to announce the “good news”

.

Exogenous cd-24 protein is packaged in exosomes and directly transported to patients’ lungs by nasal inhalation to eliminate the fatal “cytokine storm” caused by new coronavirus

.

After the outbreak lasted for one year, as people’s understanding of the virus becomes more and more comprehensive, there should be a more comprehensive assessment of the sudden emergence of “specific drugs”

.

Picture from the news report doubt cloud 1: 30 patients are cured, can represent 100% effective? It should be noted that EXO-CD24 is not an antiviral drug that eradicate the virus, rather than acting directly on New Coronavirus, but acting as an inhibitor of the body’s immune system

.

In the safety report, FDA pointed out that hydroxychloroquine is not only useless but also harmful to patients with new crowns, including blood and lymphatic system disorders, kidney damage, liver problems and failure

.

It has lasted nearly 1 years from being accused of “effective”

.

Exo-cd24 is an innovative compound based on cd-24 exosomes

.

The drug is suitable for moderate to severe patients with new crown

.

In May 2020, the local media in Tel Aviv, Israel reported that the scientists of IIBR said that two drugs (cerdelga and venglustat) used to treat Gaucher’s disease can effectively resist the new coronavirus and may be used as broad-spectrum antiviral drugs in future coronavirus outbreaks

.

In addition, the final death of patients infected with New Coronavirus pneumonia is due to the cytokine storm caused by the virus or the damage done by COVID-19 itself to the human body

.

As for the news of Israel’s “special drug”, Zhang Ping, who is certified as “tenured professor of East Asian Studies Department of Tel Aviv University” by microblog, said that at present, it is only clinical stage one, and the sample is too small, so it is difficult to say whether it can be used in the end

.

“Special effects” appeared in succession, but they were not tested by viruses

.

After 3 to 5 days of treatment, 29 of the 30 patients with moderate to severe new crowns were cured, with a cure rate of 95%

.

Whether it is the research and development of new drugs or the new use of old drugs, it is necessary to go through time-consuming and laborious clinical verification, and come up with loud and effective data

.

At the beginning of the epidemic, people were not aware of the strange casual visitor of New Coronavirus

.

The role of cd-24 protein is to act as a brake in the human immune system and inhibit excessive immune response

.

In June 2020, the emergency use of hydroxychloroquine was revoked by FDA

.

The rest of the patients took a little longer to recover, with a cure rate of 100%

.

According to the information of titanium media, other drugs known as “effective” include hydroxychloroquine, dexamethasone, etc

.

Exo-cd24 will undergo a phase II clinical trial to provide more efficacy and safety data, izirov Medical Center said

.

It is certain that since exo-cd24 is directly delivered to the lungs of patients and acts on the immune system, the immune system of patients receiving the drug must be normal, and the degree of pulmonary infection should also be required, which may be a basis for the population division of the drug

.

Reed Wei Wei novel coronavirus pneumonia is an antiviral drug

.

Titanium media TMTPost.com New drugs can control the “cytokine storm” in five days, and Israel is constantly innovating

.

Exo-cd24 belongs to the second category

.

In terms of new crown drugs, it is not known whether Israel’s “blundering shot” will be terminated from exo-cd24, which needs more large-scale clinical phase II and phase III patients to be enrolled for drug administration to verify

.

Zhao hejuan, founder of titanium media, personally gives you the welfare of the year of the ox! Red envelopes are issued for eight consecutive days in the new year of the ox

.

In August, Gilead radi, chief operating officer of Israel Redhill biopharmaceutical Co., Ltd., said that the company hopes that the drug opaganib based on the molecule can effectively treat the fatal diseases caused by the new coronavirus

.

One is antiviral drugs, which directly target the new coronavirus in patients, the other is drugs to calm the immune system, and the third is antibodies against the new coronavirus, which are extracted from the blood of patients with new coronavirus or manufactured in the laboratory

.

In the ichilov hospital in Tel Aviv, exo-cd24 carried out the first phase of clinical trials

.

Strictly speaking, there is no final conclusion

.

BGR, a US technology media, previously reported that the new coronavirus will invade the immune system of patients, aggravate the reaction in severe patients, and eventually lead to multiple organ failure and death

.

But there is no new good news about the research and development of these drugs and the progress of targeted trials

.

However, according to the existing information, in the first phase of exo-cd24 administration, Israel did not fully disclose the specific information of patients, including the age of patients, whether they have chronic diseases, and the specific direction of severe patients in their context

.

Finally, who said in November last year that Reed Wei Wei had no significant effect on the survival rate of new crown pneumonia patients

.

The expression of exo-cd24 “suitable for moderate to severe patients with new crown” is too vague

.

Is this reliable? Yang Yaru, editor of Ti media, recently announced that Israeli embassy in China has successfully developed a new drug, exo-cd24, to deal with the new coronavirus

.

It is suggested that doctors should not use Reed Wei Wei for new crown treatment

.